Previous Close | 4.9500 |
Open | 5.3958 |
Bid | 0.0000 x 1100 |
Ask | 0.0000 x 900 |
Day's Range | 4.9500 - 5.3958 |
52 Week Range | 3.3200 - 8.4900 |
Volume | 3,574 |
Avg. Volume | 4,996 |
Market Cap | 73.569M |
Beta (3Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
Largest insider trades of the week Continue reading...
President and CEO of Vaccinex Inc (30-Year Financial, Insider Trades) Maurice Zauderer (insider trades) bought 183,824 shares of VCNX on 07/30/2019 at an average price of $4.08 a share. Continue reading...
A look at the shareholders of Vaccinex, Inc. (NASDAQ:VCNX) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning Read More...